Drug and Therapeutics Bulletin 1996;34:9-11; doi:10.1136/dtb.1996.3429
Copyright © 1996 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Interferon beta-1b - hope or hype?

Relevant BNF section: 8.2.4

In November 1995, the European Commission gave approval for interferon beta-1b (Betaferon - Schering) to be marketed throughout the European Union "for the reduction of frequency and degree of severity of clinical relapses in ambulatory patients with relapsing/remitting multiple sclerosis". The drug was launched in the UK in December, with the manufacturer claiming it to be "a significant step forward in the treatment of multiple sclerosis". We review the clinical data on the effectiveness of interferon beta-1b and assess its place in the management of multiple sclerosis.

This article has been cited by other articles:

				{blacktriangledown}Natalizumab for multiple sclerosis? DTB, September 1, 2008; 46(9): 69 - 72. [Abstract] [Full Text] [PDF]

				T. Greenhalgh How to read a paper: Papers that report drug trials BMJ, August 23, 1997; 315(7106): 480 - 483. [Full Text]